Want to see AU:TRI full AI Analyst Report?
TRI Stock Chart & Stats
AU$0.02
<AU$0.01(6.67%)
At close: 4:00 PM EST
AU$0.02
<AU$0.01(6.67%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.04
Previous CloseN/A
Volume87.40K
Average Volume (3M)1.22M
Market Cap
AU$20.77M
Enterprise ValueAU$25.46M
Total Cash (Recent Filing)AU$3.47M
Total Debt (Recent Filing)AU$148.82K
Price to Earnings (P/E)―
Beta2.44
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,153,693,500
10 Day Avg. Volume1,871,965
30 Day Avg. Volume1,217,195
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)0.82
Price to Sales (P/S)0.00
P/FCF Ratio-54.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative LeverageA very low debt-to-equity ratio (~0.013 in FY2025) meaningfully reduces near-term solvency and interest-rate risk. For a pre-revenue healthtech operator, low leverage preserves strategic optionality and access to capital without heavy fixed servicing costs, supporting longer runway.
Solid Capital BaseAn equity base of roughly 12.65M and assets ~13.48M provide a durable capital cushion to fund development and regulatory steps. This balance-sheet strength supports continued R&D and potential commercialization efforts while limiting immediate dilution or distress-driven financing.
Improving Cash BurnFree cash flow tightened substantially from -3.70M to -0.19M, and FY2025 FCF is roughly in line with net losses. This indicates operating discipline or lower cash intensity, which if sustained, reduces future financing needs and increases the chance to reach break-even without excessive capital raises.
Bears Say
No Reported RevenueZero reported revenue across reported periods means the commercial model is unproven and the company lacks demonstrable product-market traction. Without recurring revenues, the firm relies on financing or milestones, making sustainable operations and scaling uncertain over the medium term.
Persistent Operating LossesConsecutive net losses and negative EBIT/EBITDA show the cost base exceeds current activity. Even with year-over-year improvement, ongoing unprofitability implies structural margin issues or immature revenue streams, requiring material revenue ramps or cost restructuring to reach sustainable profitability.
Negative Cash GenerationNegative operating and free cash flow indicate the business is not self-funding and remains dependent on external capital. Continued cash outflows increase dilution or refinancing risk and constrain investment in commercialization unless the company can convert development progress into revenue or secure committed funding.
TrivarX Limited News
TRI FAQ
What was TrivarX Limited’s price range in the past 12 months?
TrivarX Limited lowest share price was <AU$0.01 and its highest was AU$0.04 in the past 12 months.
What is TrivarX Limited’s market cap?
TrivarX Limited’s market cap is AU$20.77M.
When is TrivarX Limited’s upcoming earnings report date?
TrivarX Limited’s upcoming earnings report date is Aug 27, 2026 which is in 42 days.
How were TrivarX Limited’s earnings last quarter?
TrivarX Limited released its earnings results on Feb 24, 2026. The company reported -AU$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.002.
Is TrivarX Limited overvalued?
According to Wall Street analysts TrivarX Limited’s price is currently Overvalued.
Does TrivarX Limited pay dividends?
TrivarX Limited does not currently pay dividends.
What is TrivarX Limited’s EPS estimate?
TrivarX Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TrivarX Limited have?
TrivarX Limited has 1,153,693,500 shares outstanding.
What happened to TrivarX Limited’s price movement after its last earnings report?
TrivarX Limited reported an EPS of -AU$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -8.696%.
Which hedge fund is a major shareholder of TrivarX Limited?
Currently, no hedge funds are holding shares in AU:TRI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TrivarX Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:TRI Sentiment 100%
Sector Average 67%
Sector Average 67%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
-7.84%
Trailing 12-Months
Asset Growth
112.47%
Trailing 12-Months
Company Description
TrivarX Limited
Operating as a health technology enterprise, TrivarX Limited specializes in crafting artificial intelligence-driven, scientifically validated instruments designed for the assessment and identification of behavioral health disorders. Its market presence extends across Australia and the United States. The company delivers mental well-being provisions tailored for corporate clients through its enterprise health offerings, concurrently developing solutions for medical service providers. Established in 1987, the entity was formerly known as Medibio Limited until its rebranding as TrivarX Limited in October 2023. Its principal place of business is situated in Mount Lawley, Australia.
Technical Analysis
Resonance Health Ltd
―
Opyl Ltd.
―
MedAdvisor Limited
―
InteliCare Holdings Limited
―
PainChek Ltd
―